Literature DB >> 35164799

A boy with blistering of sun-exposed skin and finger shortening: the first case of Variegate Porphyria with a novel mutation in protoporphyrinogen oxidase (PPOX) gene in Iran: a case report and literature review.

Mohammad Vafaee-Shahi1, Saeide Ghasemi2, Aina Riahi3, Zahra Sadr4.   

Abstract

Variegate Porphyria (VP) is an inherited rare disorder that is caused by mutations in the protoporphyrinogen oxidase (PPOX) gene. This deficiency is associated with the accumulation of porphyrins and porphyrin precursors in the body, which, in turn, can potentially result in a variety of skin and neurological symptoms. Here, we reported a 7-year-old boy with homozygous VP and novel mutation on PPOX gene. He was admitted with three episodes of generalized tonic-clonic seizure in the last 6 months. He was presented with lesions, hyperpigmentation, fragility, and blistering of sun-exposed skin. The weakness of limbs and brachydactyly were observed. In the follow-up, he had aggressive behavior, learning disability and abdominal pain, particularly around the navel. Eventually, the whole exome sequencing (WES) result reported a novel homozygous pathogenic variant (c.1072G > A p.G358R) in PPOX gene which confirmed the VP. He had been advised to be away from the sun and use sunscreen regularly.
© 2022. The Author(s).

Entities:  

Keywords:  Homozygote mutation; PPOX gene; Seizure; Variegate Porphyria; skin and neurological symptoms

Mesh:

Substances:

Year:  2022        PMID: 35164799      PMCID: PMC8842551          DOI: 10.1186/s13052-022-01215-8

Source DB:  PubMed          Journal:  Ital J Pediatr        ISSN: 1720-8424            Impact factor:   2.638


Introduction

The porphyria are a group of genetic rare metabolic disorders which are characterized with a wide range of clinical symptoms based on specific subtype [1]. This disease is associated with overproduction of porphyrins due to genetic mutations of enzymes involved in heme biosynthetic pathway. Variegate porphyria (VP) is one of a group of porphyrias caused by mutations in protoporphyrinogen oxidase (PPOX) gene [2]. The typical prevalence of VP is 0.5 per 100,000; however, its prevalence in South Africa is as high as 3 per 1000 [3]. This defect is associated with accumulation of porphyrin or its precursors and results in a variety of symptoms that vary from one person to another [4]. Patients may present with skin and neurological symptoms. Common cutaneous symptoms include fragility and blistering of sun-exposed skin, but vomiting, nausea, constipation, abdominal pain, anxiety, restlessness and seizures, as well as pain and weakness are the most common neurological symptoms [5]. Studies show that various PPOX gene mutations are responsible for VP in different families [6]. Although the genetic mutation of PPOX is inherited as an autosomal dominant trait, many individuals do not exhibit any symptoms. Although VP incidence is very rare, early diagnosis of different variants and treatment of the disease is important. Here, we report a 7-year-old Iranian boy presented with multiple clinical features and a homozygous pathogenic variant in the PPOX gene, c.1072G > A (p.G358R).

Case presentation

A 7-year-old boy was admitted to our hospital with three episodes of generalized tonic seizure (GTC) in the last 6 months. He didn’t have fever in each episode. His standard laboratory test results were normal without electrolytes imbalance. On physical examination, he was shorter than average. He had coarse and hairy facial features (Fig. 1). Cutaneous symptoms, including erosive lesions scars, hyperpigmentation, fragility and blistering of sun-exposed skin, and thickened skin on hands and feet were observed (Fig. 2). He had presented with weakness of limbs, tremor of the legs while walking and brachydactyly. He was the second child of the family (II/III) from parents with consanguineous marriage. He was born from a normal vaginal delivery method with birth weight of 3 kg. The patient past medical history revealed that he has had developed with skin lesions when he was 2 year old. He was also admitted to a local hospital and received anti-seizure drug due to episodes of generalized tonic-clonic seizure (GTC). She had also a history of delayed developmental milestones and started walking by 3 years old. His first episode of generalized tonic-clonic seizure was occurred when he had 3 years old.
Fig. 1

The facial of the patient with coarse and hairy features

Fig. 2

Cutaneous symptoms on hands and feet. Erosive lesions scars, hyperpigmentation, fragility and blistering of sun-exposed skin, and thickened skin were observed

The facial of the patient with coarse and hairy features Cutaneous symptoms on hands and feet. Erosive lesions scars, hyperpigmentation, fragility and blistering of sun-exposed skin, and thickened skin were observed An electroencephalogram (EEG) was performed and revealed abnormal results due to some epileptiform discharges (EDs). The brain magnetic resonance imaging (MRI) reported severe delayed myelination. Differential diagnoses included xeroderma pigmentosum and Cockayane syndrome. The patient had received phenobarbital and seizure was completely controlled. Because of skin lesions, dermatologist recommended a skin biopsy for the possibility of xeroderma pigmentosum. The skin biopsy test result reported the subepidermal bullae compatible with erythropoietic porphyria. Molecular test analysis with whole exome sequencing (WES) was performed to consider any possible mutations. The WES result reported a novel homozygous pathogenic variant (c.1072G > A p.G358R) in PPOX gene which indicates the Porphyria Variegate. This pathogenic variant has not been reported previously. In the follow-up, after completing 2 years of treatment, phenobarbital was tapered, but he had developed another episode of status GTC and admitted at hospital. Brian MRI was immediately done and showed normal results. Since it was better not to use phenobarbital for this case, treatment with levetiracetam has been started. To improve skin symptoms, he had been advised to be away from the sun and use sunscreen regularly. He had also aggressive behavior, learning disability and abdominal pain, particularly around the navel.

Discussion

Variegate porphyria is a very rare and autosomal dominant disorder which is caused by the mutations in protoporphyrinogen oxidase. PPOX is one of the fundamental enzymes responsible for the synthesis of heme, as a main part of hemoglobin and other hemoproteins. Porphyrins are essential for hemoglobin function. When PPOX is deficient, porphyrins are oxidized to protoporphyrin and coproporphyrin, transported in the blood plasma and cause higher sensitivity of the skin to sunlight. VP symptoms usually start in adulthood and vary from person to person (Table 1) [17]. It may be associated with skin symptoms, neurological symptoms or both. Sun sensitivity, blisters, sores and discoloration after sun exposure are the most common type of skin symptoms in patients with VP. Acute attacks are neurological symptoms that may occur as a consequence of exposure to hormonal changes, certain medications and dieting. Abdominal pain, nausea, vomiting, diarrhea and constipation are the other symptoms that a person with VP my experience. Weakness of muscles, seizures, hypertension and increased heart rate may also occur (Table 1). Anxiety and hallucinations have been reported as mental changes [18].
Table 1

The most common clinical symptoms of VP reported by previous studies

CasesSkin symptomsOther clinical findingsRefs
A 30-year-old womanRepeated vesicles and brownish pigmentation; brownish pigmentations and crusts in hands and forearmsWeakness and dysesthesia in all limbs; hallucination; urinary disturbance; dark-red urine[7]
A 9-month girlBlistering of the face and hands; erosions; crusting; pigmentation and milia; scarring of sun-exposed areas; thickened and infiltrated skinElevated erythrocyte protoporphyrin; marked foreshortened; stubby fingers and toes; brachydactyly; delayed motor development;[8]
A male infantBlistering and fragility of the skin of hands, face and ears; hypertrichosis; hyperpigmentation; scarring and milia;Epilepsy; developmental delay; nystagmus and clinodactyly[8]
A 14-year-old girlPhotosensitivityMental retardation; clinodactyly; enhanced erythrocyte protoporphyrin concentration[9]
A 7-year-old boySevere photosensitivity; skin fragility, blistering, erosions and pronounced scarring in sun-exposed body areasBrachydactyly; raised proto-porphyrin concentrations;[10]
A 73 years old womanCutaneous eruptions to the sun-exposed areas; increased facial pigmentationAcute abdominal pains and bloating[11]
A 25-year-old femaleRash; bullous lesions in the light exposed area

Dark coloured urine; nausea and vomiting; afebrile; attack

of abdominal pain; constipation

[12]
An Italian casePhotosensitivity; photomutilations;mental retardation; aphasia and aggressivity[13]
A 35 years old femaleBlister formation after sun exposure;Reddish urine; abdominal pain, nausea, vomiting and seizures; muscular weakness; Amyloid A amyloidosis[14]
A 12-year-old femaleBlistersEpilepsy; mental retardation; premature adrenarche; death[15]
A 23-year-old femaleItchy blisters in face and upper limbs; scarring; erythematous maculopapular lesions; cutaneous porphyria, cutaneous lupus, drug-induced photosensitivity, epidermolysis bullosa acquisita and actinic prurigoExcess protoporphyrin and coproporphyrin in stool
A 36-year-old womancutaneous manifestations; photosensitivityElevated erythrocyte protoporphyrin[16]
A 24-year-old femaleBlisters; superficial erosions; haemorrhagic crusts, milia and patchy hyper pigmentation of the extensor sites of fingers and hands; skin fragilityNo neurological symptoms; enhanced urinary coproporphyrin; faecal protoporphyrin excretion; decrease of porphobilinogen deaminase activity; dark urine; coproporphyrin and faecal protoporphyrin excretion
The most common clinical symptoms of VP reported by previous studies Dark coloured urine; nausea and vomiting; afebrile; attack of abdominal pain; constipation To the best of our knowledge, around 15 cases with homozygous VP have been reported worldwide. Here, we reported the first case of homozygous VP with novel mutation on PPOX gene in Iran. Our case had a history of GTC episodes with the history of developmental delay. Similarly, Hif et al., [8] reported a VP case who developed epilepsy at 5 months and developmental delay. Our case had a coarse and hairy facial feature. The most common skin symptoms in our patient were erosive lesions scars, hyperpigmentation, fragility and blistering of sun-exposed skin, as well as thickened skin on hands and feet. Weakness of limbs, tremor of the legs while walking and brachydactyly were the other findings in this case. Hif et al., [8] reported blistering and fragility of the face and hands, hyperpigmentation, hypertrichosis, erosions, crusting, pigmentation and milia, scarring of sun-exposed areas, as well as foreshortened, stubby fingers and toes, brachydactyly, delayed motor development as the most common skin and neurological symptoms in two cases with VP. In the follow-up, our case showed aggressivity learning disability. A previous study reported mental retardation in a 14-year-old girl [9]. A more recent study has reported mental retardation and aggressive behavior in an Italian case during a long-term follow up [13]. Shimizu et al., [7] reported a 30-year-old woman with VP who had multiple skin and neurological symptoms. Repeated vesicles and brownish pigmentation on upper extremities were the most common skin symptoms in this case. Moderate weakness, dysesthesia and hyperreflexia in all limbs were the most common neurological findings in this patient. Some studies reported reddish and dark colored urine in patients with VP [12, 14]. Tsuchiya et al., [14] found the existence of amyloid and amyloidosis in a 35-year-old woman with VP which was complicate with end-stage renal failure and gastrointestinal symptoms. A previous study reported a young VP case with epilepsy, mental retardation and premature adrenarche symptoms, but death occurred later [15]. Hepatocellular carcinoma in VP has been described in at least eight cases with VP, indicating the risk of cancer in these patients [19]. All of these data emphasize that there are various skin and neurological symptoms in these patients. There are patients who may have minor symptoms without remarkable clinical manifestations. The severity of VP symptoms feasibly depends on the type of PPOX mutations. Therefore, early diagnosis and treatment the clinical features of the disease are important to improve the quality of life among these cases. Some studies reported different missense mutations in the PPOX gene which were correlated to VP occurrence. A previous study identified two underlying missense mutations in the PPOX gene, consisting of a G-to-A transition in exon 6 (G169E), and a G-to-A transition in exon 10 (G358R), which were correlated to homozygous VP [17]. In another study, Roberts et al., [20] reported two missense mutations (D349A and A433P) in PPOX gene which may be correlated to VP without clinical penetrance in heterozygotes. Poblete-Gutierrez et al., [10] found two different mutations in exon 7 and exon 13 of the PPOX gene in a 7-year-old boy. More recently, Bonuglia et al., [13] reported a novel mutation in PPOX gene (1061C > T/397G > A) in an Italian case. Another study showed two novel mutations in PPOX gene (c. 657–658 insertion and IVS 11–1 G → A transition) in a 36-year-old woman with VP [16]. Therefore, these findings emphasize the importance of molecular genetic testing to find any mutations in PPOX gene and their correlation to VP occurrence and disease severity. More importantly, the genetic basis of the disease should be considered. Although no evidence of similar conditions was reported in our patient’s family, he was born from parents with consanguineous marriage. Therefore, elucidation of the genetic basis in this family is important for genetic counselling. Moreover, each child of an individual with VP has a 50% chance of inheriting the mutation [11]. Offspring who inherit the PPOX mutation may be more or less severely affected than their parent. Therefore, we believe that the case presented herein under-lines the overall importance of genetic studies in the porphyrias.

Conclusion

Here, we reported the first Iranian case of homozygous VP with a novel mutation on PPOX gene. Various skin and neurological symptoms may be found in these patients, which are probably due to different mutations in PPOX genes. Therefore, further studies are necessary to evaluate the relationship between genotype and phenotype of the disease. The VP diagnosis is firstly depends on clinical findings, especially skin and neurological symptoms. Once a case is suspected of having VP, extra laboratory tests on urine, blood and stool can be performed. As most studies reported elevated protoporphyrin levels in cases of homozygous VP, measurement of protoporphyrin or coproporphyrin in the blood, urine and stool is helpful. However, the most sensitive screening test is the assessment of plasma porphyrin. Genetic testing of PPOX gene is valuable to confirm the disease diagnosis. Interestingly, our patient was born from parents with consanguineous marriage; however, no evidence of similar conditions was reported in his family. Since consanguineous marriage is common in Iran, there may be a relationship between the incidence of VP and consanguineous marriage. Therefore, further considerations are required to evaluate the correlation. Therefore, premarital genetic counseling and education may be helpful. Avoiding excess sun exposure can reduce the blisters and skin lesions in these cases.
  19 in total

1.  A case of variegate porphyria in an Indian.

Authors:  F Handa; K Kumar; R Kumar
Journal:  Br J Dermatol       Date:  1975-03       Impact factor: 9.302

Review 2.  Homozygous variegate porphyria: identification of mutations on both alleles of the protoporphyrinogen oxidase gene in a severely affected proband.

Authors:  J Frank; J McGrath; H Lam; R M Graham; J L Hawk; A M Christiano
Journal:  J Invest Dermatol       Date:  1998-04       Impact factor: 8.551

3.  Homozygous variegate porphyria: a case report.

Authors:  P G Norris; G H Elder; J L Hawk
Journal:  Br J Dermatol       Date:  1990-02       Impact factor: 9.302

4.  An unusual case of variegate porphyria with possible homozygous inheritance.

Authors:  J Coakley; R Hawkins; N Crinis; J McManus; D Blake; Y Nordmann; L Sloan; J Connelly
Journal:  Aust N Z J Med       Date:  1990-08

Review 5.  A review of the clinical presentation, natural history and inheritance of variegate porphyria: its implausibility as the source of the 'Royal Malady'.

Authors:  Richard J Hift; Timothy J Peters; Peter N Meissner
Journal:  J Clin Pathol       Date:  2011-11-02       Impact factor: 3.411

Review 6.  Variegate porphyria.

Authors:  R E Kirsch; P N Meissner; R J Hift
Journal:  Semin Liver Dis       Date:  1998       Impact factor: 6.115

7.  [A case report of variegate porphyria].

Authors:  H Shimizu; H Miyajima; M Kondo; N Sakai; T Kamata
Journal:  Rinsho Shinkeigaku       Date:  1995-11

8.  An analysis of 112 acute porphyric attacks in Cape Town, South Africa: Evidence that acute intermittent porphyria and variegate porphyria differ in susceptibility and severity.

Authors:  Richard J Hift; Peter N Meissner
Journal:  Medicine (Baltimore)       Date:  2005-01       Impact factor: 1.889

9.  A case of variegate porphyria in association with coeliac disease and bisphosphonate associated dental osteonecrosis.

Authors:  Olayinka A Ogundipe
Journal:  J Clin Med Res       Date:  2009-12-28

10.  Variegate porphyria complicated by systemic AA amyloidosis: a case report.

Authors:  Yoshiki Tsuchiya; Junichi Hoshino; Tatsuya Suwabe; Keiichi Sumida; Rikako Hiramatsu; Koki Mise; Eiko Hasegawa; Masayuki Yamanouchi; Noriko Hayami; Naoki Sawa; Kenji Arizono; Shigeko Hara; Kenmei Takaichi; Takeshi Fujii; Yoshifumi Ubara
Journal:  Amyloid       Date:  2013-10-16       Impact factor: 7.141

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.